Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab

Blumenthal, Deborah T.; Kanner, Andrew A.; Aizenstein, Orna; Cagnano, Emanuela; Greenberg, Ariel; Hershkovitz, Dov; Ram, Zvi; Bokstein, Felix

doi:10.1016/j.wneu.2017.11.105

Cited by 13 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Median OS from recurrent surgery of pre-surgery BEV treated groups was longer than that of the post-surgery group. [ 52 ] 2019, Prelaj et al Retrospective study rGBM (first recurrence) 26 (100%) BEV combined therapy concomitant FTM/BEV vs. sequential FTM/BEV No significant difference. [ 104 ] 2020, Seystahl et al Retrospective study rGBM (first recurrence) 344 (100%) BEV combined therapy Alkylators first and BEV at any further recurrence vs. BEV first and alkylators at further recurrence OS benefits were observed in alkylators first and BEV at any further recurrence.…”

Section: Resultsmentioning

confidence: 99%

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Zhou

Huang

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no evidence for its ability to prolong overall survival (OS). Given the uncertainty surrounding BEV treatment strategies, we aimed to provide an evidence map associated with BEV therapy for recurrent GBM (rGBM). Methods PubMed, Embase, and the Cochrane Library were searched for the period from January 1, 1970, to March 1, 2022, for studies reporting the prognoses of patients with rGBM receiving BEV. The primary endpoints were overall survival (OS) and quality of life (QoL). The secondary endpoints were PFS, steroid use reduction, and risk of adverse effects. A scoping review and an evidence map were conducted to explore the optimal BEV treatment (including combination regimen, dosage, and window of opportunity). Results Patients with rGBM could gain benefits in PFS, palliative, and cognitive advantages from BEV treatment, although the OS benefits could not be verified with high-quality evidence. Furthermore, BEV combined therapy (especially with lomustine and radiotherapy) showed higher efficacy than BEV monotherapy in the survival of patients with rGBM. Specific molecular alterations (IDH mutation status) and clinical features (large tumor burden and double-positive sign) could predict better responses to BEV administration. A low dosage of BEV showed equal efficacy to the recommended dose, but the optimal opportunity window for BEV administration remains unclear. Conclusions Although OS benefits from BEV-containing regimens could not be verified in this scoping review, the PFS benefits and side effects control supported BEV application in rGBM. Combining BEV with novel treatments like tumor-treating field (TTF) and administration at first recurrence may optimize the therapeutic efficacy. rGBM with a low apparent diffusion coefficient (ADCL), large tumor burden, or IDH mutation is more likely to benefit from BEV treatment. High-quality studies are warranted to explore the combination modality and identify BEV-response subpopulations to maximize benefits.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Zhou

Huang

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Despite the increased response rates of GB to biological agents, including anti-angiogenic monoclonal antibodies and tumor-vasculature-targeting agents such as bevacizumab, these biological agents do not provide a survival advantage. In addition to all currently available conservative treatment modalities, the degree of surgical resection provides a limited contribution to the survival of the patients (4,45). The failure to improve overall survival with multimodal treatment methods and the low average survival rate remain major problems in the treatment of malignant GB.…”

Section: █ Resultsmentioning

confidence: 99%

Systematic evaluation of promising clinical trials—gene silencing for the treatment of glioblastoma

Karaarslan

Yılmaz²,

Özbek³

et al. 2018

Turkish Neurosurgery

View full text Add to dashboard Cite

show abstract

“…Although the mechanism in the pathogenesis of glioma remained undetermined, accumulating evidence suggested that a large number of circRNAs and miRNAs were involved in the pathogenesis of glioma. Previous studies have revealed that circRNAs could modulate gene expression by acting as miRNAs sponges in various tumors (1, 9, 37). For instance, hsa_circ_0007534 promoted the progression of glioma through the miR-761/ZIC5 regulatory loop (29).…”

Section: Discussionmentioning

confidence: 99%

CircPCMTD1 Acts as the Sponge of miR-224-5p to Promote Glioma Progression

Zheng

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

Glioma is the most common malignant tumor of the central nervous system with high morbidity and mortality. Circular RNAs (circRNAs) are abundant non-coding RNAs, which contribute to tumor progression by competing with other endogenous RNAs such as microRNA (miRNA). MiRNA are a class of small non-coding RNAs, which interrupt the translation of target mRNAs. CircPCMTD1 (hsa-circ-0001801) is a newly discovered circRNA that was found to be significantly upregulated in glioma. However, its function is unclear. In this study, circPCMTD1 upregulation promoted the cell viability, migration and invasion dramatically, while the inhibition of circPCMTD1 led to a significant reduction of tumor growth in vivo . MiRNAs microarray analyses on circPCMTD1 silencing models in U251 and U118MG cells were performed, and the results suggested that circPCMTD1 knockdown could upregulate the expression of miR-224-5p and downregulate the expression of mTOR, one of miR-224-5p targets, in both cell lines. According to the prediction from circular RNA interactome and Targetscan, there was a complementary sequence in circPCMTD1 for miR-224-5p. Dual-luciferase reporter assay demonstrated that circPCMTD1 were targets of miR-224-5p. RIP assay was also performed to further confirm their directly interaction. Overexpression of miR-224-5p inhibited the viability and proliferation, migration, and invasion of U251 and U118MG glioma cells. In conclusion, circPCMTD1 could contribute to the promotion of glioma progression, and it may serve as the sponge of miR-224-5p to exert its function.

show abstract

Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab

Cited by 13 publications

References 41 publications

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Systematic evaluation of promising clinical trials—gene silencing for the treatment of glioblastoma

CircPCMTD1 Acts as the Sponge of miR-224-5p to Promote Glioma Progression

Contact Info

Product

Resources

About